局部止痛藥的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Topical Analgesic Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 851196
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
局部止痛藥的全球市場 - 成長,趨勢,預測(2019年∼2024年) Topical Analgesic Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 111 Pages




第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 關節炎的盛行率增加
    • 運動相關障礙的增加
    • 老年人口的增加
  • 市場阻礙因素
    • 局部止痛藥相關的副作用
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各醫藥品類型
    • 非類鴉片物質
    • 類鴉片物質
    • 其他
  • 各形狀
    • 乳膏
    • 貼片
    • 噴霧
    • 凝膠
    • 其他
  • 各類型
    • 一般用醫藥品
    • 醫療用醫藥品
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • AdvaCare Pharma
    • GlaxoSmithKline plc.
    • Johnson & Johnson
    • Pfizer Inc.
    • 久光製藥
    • Sanofi
    • Sun Pharmaceutical Industries Ltd
    • Topical BioMedics, Inc.
    • Teva Pharmaceutical Industries Ltd

第7章 市場機會及未來趨勢


Product Code: 66139

Market Overview

The topical analgesic market (hereafter, referred to as the market studied) is expected to witness a CAGR of 7.43% during the forecast period. Certain factors that are driving the market growth include increasing prevalence of arthritis, rising cases of sports-related injuries, and growing geriatric population.

A sports injury is creating a huge demand for topical analgesics among athletes. As per the Centers for Disease Control and Prevention (CDC), more than 2.6 million pediatric patients are treated in emergency departments for sports-related injuries each year. In accordance with the National Safety Council (NSC), in 2017, exercise and the use of exercise equipment led to the most of the sports-related injuries in the United States, with more than 526,000 injuries reported. The same source indicated that basketball, followed with about 500,000 injuries, while bicycling, with 457,000 injuries and football, with 341,000 injuries, ranked third and fourth. Topical options for sports-related injuries act as convenient alternative or adjunct to oral medications, since they provide pain relief with minimal systemic adverse events.

Other factors, such as rising geriatric population and increasing prevalence of arthritis are also expected to drive the market studied over the forecast period.

Although the adverse effects arising from topical pain relief products are rare, skin irritation and other complication might restrict its usage and consequently affects the market growth. Some common side effects are stinging of skin and dry skin problem. Apart from these, burning sensation, hypersensitivity drug reaction, hives might occur.

Scope of the Report

Topical analgesics are recommended to use when patients experience acute and chronic muscle and joint pain, in order to get relief from their symptoms. The products are applied directly to the skin, instead of being injected or swallowed. The topical analgesics are available in the forms of creams, lotions, spray, gel, or patch. The topical analgesics are obtained as prescription analgesics and OTC analgesics as well. The OTC topical analgesics are intended to treat mild to moderate pain for not more than 7 days unless otherwise directed by a physician. However, several factors must be considered when selecting an OTC topical analgesic, which include dosage form, cost, ease of use, odor, and the patient's medical history, including possible allergies.

Key Market Trends

Non-opioids are Expected to Hold Significant Market Share in the Drug Type

In recent years, with emerging chronic pain conditions, the topical route for pain management has seen a resurgence of interest, owing to its potential to deliver therapeutic doses of medication directly to a painful site, circumventing the GI tract, and without any requirement for a needle. Topical NSAIDs are found to be more effective in treating acute pain from strains, sprains, contusions, or overuse injuries in superficial locations. Various formulations of topical diclofenac are available in the market for the treatment of acute and chronic pain, including Voltaren gel, Pennsaid solution, and Flector patch, and are used in the setting of osteoarthritis or musculoskeletal pain. As per the recommendation of National Institute for Health and Care Excellence (NICE), topical NSAIDs in the first instance for joint pain associated with osteoarthritis, in preference to oral NSAIDs are prescribed by the healthcare professionals, owing to concerns over systemic side effects caused by the long term use of oral NSAIDs.

This makes topically applied NSAIDs to be the first choice for physicians in the initial treatment of pain and which further creates immense commercial opportunity in the present market.

The Market is Dominated by North America and is Expected to do Same in the Forecasted Period

North America is estimated to dominate the industry, owing to well-established healthcare facilities, rising geriatric population, and growing prevalence of chronic pain. In recent years, it has been found that pain affects more Americans than diabetes, heart disease, and cancer combined, which further influence adults to seek medical care. Pain is one of the key reasons behind the leading cause of disability and a major contributor to health care costs in the United States. As per the data provided by the Centers for Disease Control and Prevention (CDC), chronic pain range from 11% to 40% among the adults of the United States. The high prevalence of chronic pain thus indicates the importance of topical pain relief products and consequently helps to drive its market. Apart from this, the growing prevalence osteoarthritis acts as one of the key driving factors of the topical analgesic market in the United States, which affects around 30 million US adults. In the United States, the Food and Drug Administration (FDA) has approved several topical products that contain the prescription NSAID diclofenac in the form of gels, liquids, and patches for the treatment of osteoarthritis.

Competitive Landscape

The topical analgesic market is highly competitive and consists of a number of major players. Companies like GlaxoSmithKline plc., Johnson & Johnson, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and AdvaCare Pharma among others, hold the substantial market share in the topical analgesic market.

Various developments have recently been taking place in the market, such as in March 2019, Teva Pharmaceutical Industries Ltd, announced the launch of an authorized generic of Flector 1 Patch, 1.3%, in the US Diclofenac Epolamine Topical Patch, 1.3%, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the topical treatment of acute pain arising from minor strains, sprains, and contusions.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Arthritis
    • 4.2.2 Rising Cases of Sports related Injuries
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Related to Topical Analgesics
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 Drug Type
    • 5.1.1 Non Opioids
      • Nonsteroidal anti-inflammatory drugs (NSAIDS)
      • Capsaicin
      • Lidocaine
      • Methyl salicylates
      • Other Drug Types
    • 5.1.2 Opioids
    • 5.1.3 Other Opioids
  • 5.2 Formulation
    • 5.2.1 Cream
    • 5.2.2 Patch
    • 5.2.3 Spray
    • 5.2.4 Gel
    • 5.2.5 Other Formulations
  • 5.3 Type
    • 5.3.1 Over the Counter (OTC) Analgesic
    • 5.3.2 Prescription Analgesic
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of MEA
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 AdvaCare Pharma
    • 6.1.2 GlaxoSmithKline plc.
    • 6.1.3 Johnson & Johnson
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Hisamitsu Pharmaceutical co.,inc.
    • 6.1.6 Sanofi
    • 6.1.7 Sun Pharmaceutical Industries Ltd
    • 6.1.8 Topical BioMedics, Inc.
    • 6.1.9 Teva Pharmaceutical Industries Ltd
    • 6.1.10 List Not Exhaustive